CIBC Asset Management Inc Reduces Stock Position in Sanofi (NASDAQ:SNY)

CIBC Asset Management Inc lessened its holdings in Sanofi (NASDAQ:SNY) by 31.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 90,417 shares of the company’s stock after selling 41,731 shares during the quarter. CIBC Asset Management Inc’s holdings in Sanofi were worth $5,211,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Stablepoint Partners LLC increased its holdings in Sanofi by 0.8% in the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock valued at $1,377,000 after buying an additional 189 shares during the last quarter. PDS Planning Inc grew its holdings in shares of Sanofi by 3.1% during the third quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock worth $383,000 after purchasing an additional 200 shares during the last quarter. Eagle Ridge Investment Management grew its holdings in shares of Sanofi by 3.8% during the third quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock worth $321,000 after purchasing an additional 203 shares during the last quarter. Financial Advocates Investment Management grew its holdings in shares of Sanofi by 3.4% during the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock worth $365,000 after purchasing an additional 206 shares during the last quarter. Finally, Angeles Investment Advisors LLC grew its holdings in shares of Sanofi by 1.9% during the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock worth $653,000 after purchasing an additional 210 shares during the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $47.97 on Monday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company has a market cap of $121.74 billion, a P/E ratio of 24.47, a PEG ratio of 1.22 and a beta of 0.61. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The company has a 50-day moving average price of $54.65 and a 200 day moving average price of $52.23.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter last year, the firm earned $2.55 earnings per share. The firm’s revenue was up 12.3% compared to the same quarter last year. Research analysts predict that Sanofi will post 4.29 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on SNY shares. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Argus increased their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Sanofi presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.